Charles River CEO reveals drop in 2025 revenue outlook at JP Morgan – Pharmaceutical Technology
Charles River Laboratories (CRL) expects its revenue to decline in 2025, the CEO revealed at the JP Morgan Healthcare Conference 2025 in San Francisco on